By Ethan Covey
The identification of three cases of pan-resistant Candida auris isolates in New York has resulted in calls for increased surveillance, reevaluation of the use of antifungal medications and the need for susceptibility testing on all clinical isolates, according to the CDC.
Pan-resistance occurs when C. auris shows resistance to all three classes of commonly prescribed antifungal medications, and has been identified in multiple countries (MMWR Morb Mortal Wkly Rep 2020;69:6-9).